Login to Your Account

Getting the Motor Running

More Hands on Molecular Deck Key to Heart Failure Treatment

By Anette Breindl

Friday, March 18, 2011
Cytokinetics Inc's lead compound, omecamtiv mecarbil, is in Phase II trials for the treatment of heart failure. In the March 18, 2011, issue of Science, researchers from Cytokinetics and colleagues at several academic institutions published details of how the drug works. Those insights may yield new treatments for heart failure as well as other diseases where muscle contraction is an issue, such as asthma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription